BeyondSpring (BYSI) Projected to Post Earnings on Thursday

BeyondSpring (NASDAQ:BYSI) will likely be posting its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect BeyondSpring to post earnings of ($0.54) per share and revenue of $8.77 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

BeyondSpring (NASDAQ:BYSI) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.52.

BeyondSpring Stock Performance

BeyondSpring stock opened at $0.68 on Thursday. The company has a market capitalization of $27.92 million, a P/E ratio of -5.66 and a beta of -0.12. BeyondSpring has a fifty-two week low of $0.42 and a fifty-two week high of $2.44. The stock has a 50-day simple moving average of $0.66 and a 200-day simple moving average of $1.26.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised BeyondSpring from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 8th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

BeyondSpring Company Profile

BeyondSpring Inc (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s lead product candidate is plinabulin, a small-molecule agent designed to provide both anticancer and immune-modulating effects.

Plinabulin has been investigated as a treatment to prevent chemotherapy-induced neutropenia, a potentially serious reduction in infection-fighting white blood cells that can occur during cancer treatment.